Home›Trial›NCT05607810
NCT05607810ACTIVE NOT RECRUITING

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Study Summary

This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 are eligible for enrollment upon completion of the end of study visit in the parent study.

Conditions
Diabetic Macular EdemaDiabetic Retinopathy
Interventions / Drugs
ADVM-022
View on ClinicalTrials.gov ↗
Sponsor
ADVM
Adverum Biotechnologies
Ophthalmology
C59/100
Study Details
Enrollment22 participants
Primary Completion—
Lead SponsorAdverum Biotechnologies, Inc.
Data Retrieved2026-04-11 02:52:31.871692+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 22 participants
Sponsor Catalyst Profile

Adverum Biotechnologies (ADVM) is the sponsoring company for this trial. BiotechSign currently grades this company C (59/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ADVM Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.